A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
Through its Health Equity and Diversity in STEM Innovation Fund, the biotech is looking to increase equity in care and diversify the scientific workforce.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
Genentech enters a manufacturing and development agreement with Enable Injections to advance the latter’s patient-administered subcutaneous drug delivery system.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
Roche is expanding its manufacturing operations to service its biologics pipeline, but the firm says it will continue to outsource approximately 20% of all production.
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
Swiss firm Roche has begun making cuts at recent $46.8bn biotech acquisition Genentech, in the first stage of a widely anticipated integration programme.
Art Levinson is to step down from his role as Genentech’s CEO but will play “an active role” at the company as part of Roche’s attempts to integrate and retain the biotech’s key staff.
Roche is closing its manufacturing facility in Nutley, New Jersey and relocating its centre of commercial operations in the US to California following its $46.8bn (€36.3bn) takeover of Genentech.
Genentech believes a far-sighted approach to patent expiration, unique and life saving drugs and an unrivalled scientific culture will protect it from recession and ensure greater growth than Roche envisions.
Genentech used its investor meeting to retaliate against criticisms made by Roche, saying it will debate its financial model “anywhere, anytime with anyone”.
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
Roche’s proposed $44bn acquisition of Genentech is facing some opposition with Wall Street saying the offer undervalues the company, disquiet among the biotech’s employees and shareholders suing the Swiss giant.
Despite Genentech's recent decision to push out the cut-off date to
ban the sale of cancer drug Avastin (bevacizumab) to compounding
pharmacies in the US to restrict off-label use, ophthalmologists
still find the firm's...
Lonza has signed two separate deals with California-based Genentech
- a move that illustrates the re-emergence of a relationship
between the two firms.
Genentech has announced that studies of Avastin in
platinum-refractory ovarian cancer patients have been discontinued
due to patients developing a serious bowel problem.
US biotechnology major Genentech has provided further detail on its
plans to dramatically increase production capacity in the wake of
its $408m acquisition of Biogen-Idec's Oceanside facility.
US biotechnology company Genentech is planning to build a new
large-scale mammalian cell culture manufacturing facility in
California which will be the largest of its kind in the world.
Genentech's strategy of expanding beyond its traditional territory
of protein-based drugs and into small molecules was reinforced
earlier this week by its new agreement with Array BioPharma.
Switzerland's Lonza has won a long-term manufacturing contract from
US biotechnology bellwether Genentech for Rituxan (rituximab) a
biological drug which recorded worldwide sales of $1.48 billion in
2002.
